- Home
- PTGX
as 03-28-2025 4:00pm EST
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | NEWARK |
| Market Cap: | 2.4B | IPO Year: | 2016 |
| Target Price: | $66.50 | AVG Volume (30 days): | 1.7M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 4.23 | EPS Growth: | N/A |
| 52 Week Low/High: | $24.22 - $60.60 | Next Earning Date: | 05-06-2025 |
| Revenue: | $434,433,000 | Revenue Growth: | 624.05% |
| Revenue Growth (this year): | -74.47% | Revenue Growth (next year): | 8.12% |
Stock Insider Trading Activity of Protagonist Therapeutics Inc. (PTGX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Waddill William D. | PTGX | Director | Mar 17 '25 | Sell | $54.25 | 4,000 | $217,000.00 | 13,130 | |
| MOLINA ARTURO MD | PTGX | Chief Medical Officer | Mar 13 '25 | Sell | $55.74 | 30,514 | $1,700,850.36 | 83,892 | |
| Ali Asif | PTGX | Chief Financial Officer | Mar 12 '25 | Sell | $58.73 | 24,903 | $1,462,553.19 | 62,821 | |
| PATEL DINESH V PH D | PTGX | President and CEO | Feb 19 '25 | Sell | $38.18 | 5,359 | $204,606.62 | 540,260 | |
| Ali Asif | PTGX | Chief Financial Officer | Jan 16 '25 | Sell | $0.00 | 3,918 | $0.00 | 62,821 | |
| MOLINA ARTURO MD | PTGX | Chief Medical Officer | Jan 16 '25 | Sell | $0.00 | 3,640 | $0.00 | 83,892 |
Latest Protagonist Therapeutics Inc. News
PTGX Breaking Stock News: Dive into PTGX Ticker-Specific Updates for Smart Investing
Argus Research
3 days ago
PTGX: Lowering target price to $54.00
Zacks
4 days ago
Wall Street Analysts See a 27.36% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High?
Insider Monkey
10 days ago
Analysts Mentions Growth Catalysts for Protagonist Therapeutics (PTGX) — Best Biotech Stock for 2025?
FastCompany
11 days ago
These 10 biotech companies are changing how we discover new drugs and treat complex diseases
ACCESS Newswire
11 days ago
Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025
Insider Monkey
13 days ago
Is Protagonist Therapeutics, Inc. (PTGX) the Best Healthcare Stock For Long-Term Investment?
Zacks
16 days ago
Biotech Stock Roundup: TSVT Up on BMY Deal, PTGX Up on Data & More
Zacks
17 days ago
Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's Why
Compare PTGX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PTGX Protagonist Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.